NFKB1 and pulmonary arterial hypertension: The preclinical effectiveness and clinical potential of the Nf-κB inhibitor (N-(3,5-Bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide, IMD-0354) recently have been elucidated in PAH.